Chimeric Antigen Receptor News and Research

RSS

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

From AMS Biotechnology 1 Oct 2021

Researchers engineer CAR T cells to enhance their function

Chimeric antigen receptor (CAR) T cell therapy employs engineered T cells to treat certain kinds of cancers.

7 Sep 2021

Researchers develop heat-controllable CAR T cells to kill tumors and prevent relapse

A team of researchers led by bioengineers at the Georgia Institute of Technology is expanding the precision and ability of a revolutionary immunotherapy that is already transforming oncology. CAR T-Cell therapy has been hailed by patients, clinical-researchers, investors, and the media as a viable cure for some cancers.

19 Aug 2021

Mayo Clinic researchers examine potential new CAR-T cell treatment for multiple myeloma

Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma.

28 Jun 2021

Small molecular changes can have dramatic impact on the CAR T cell function

When researchers from Penn Medicine found that many patients with B-cell acute lymphoblastic leukemia (ALL) treated with the investigational chimeric antigen receptor (CAR) T cell therapy targeting the CD22 antigen didn't respond, they went back to the drawing board to determine why.

23 Apr 2021

Researchers use mathematical modeling to explain CAR T-cell therapy dynamics

Chimeric antigen receptor T-cell therapy, or CAR T, is a relatively new type of therapy approved to treat several types of aggressive B cell leukemias and lymphomas.

26 Mar 2021

Study advances CAR T cell therapy targeted at cancer

Cancer immunotherapy involves the activation of cells in the patient’s own immune system to fight tumor cells.

19 Mar 2021

Engineered safety switch reduces CAR-T immunotherapy-related side effects

UNC Lineberger Comprehensive Cancer Center researchers have successfully used an experimental safety switch, incorporated as part of a chimeric antigen receptor T-cell (CAR-T) therapy, a type of immunotherapy, to reduce the severity of treatment side effects that sometimes occur.

5 Mar 2021

New CAR T therapy could be more effective and less toxic against neuroblastoma

CAR T therapy has transformed the treatment for leukemia. Regrettably, the therapy is not effective enough to treat solid tumors, like neuroblastoma.

22 Jan 2021

Researchers create molecular ON-OFF switches to regulate CAR T cell activity

CAR T cells are a breakthrough class of effective but often toxic cancer therapies. To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug.

7 Jan 2021

Researchers identify a vital protein needed to regulate anti-tumor immune response

Scientists from The University of Texas MD Anderson Cancer Center have identified a protein known as NF-kappa B-inducing kinase (NIK).

5 Jan 2021

Combination method can boost immunotherapy for breast cancer

According to a new study performed by scientists from the University of North Carolina, stimulating an immune signaling pathway, which is best known for combating bacterial and viral infections, can increase the potential of genetically engineered T cells to remove breast cancer in mice.

4 Jan 2021

Study: CAR T cell therapy is a safe, effective therapy for high-risk large B-cell lymphoma

A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.

8 Dec 2020

Researchers target pathogenic T cells that could lead to new immunotherapy treatments

According to a new study, a novel T cell genetically engineered by scientists from The University of Arizona Health Sciences can target and attack pathogenic T cells that are responsible for causing Type 1 diabetes. These latest findings may result in new immunotherapy therapies.

7 Dec 2020

CAR T-cell therapy reduced cancer cells in patients with advanced non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

7 Dec 2020

New method to improve preclinical evaluation of CAR-T cell therapies

Ludwig Cancer Research scientists have developed a method to significantly improve the preclinical evaluation of chimeric antigen-receptor (CAR) T cell therapies.

9 Nov 2020

Novel approach based on microfluidic technology to fight cancer

CAR-T biotherapeutics company Carina Biotech and researchers at the University of South Australia have developed a novel approach based on microfluidic technology to "purify" the immune cells of patients in the fight against cancer.

21 Oct 2020

Researchers identify drug that could overcome tumor resistance

Scientists have discovered that a drug that may make some melanoma tumors perceptible to the immune system, enabling them to be better targeted.

15 Oct 2020

Virus-mimicking drugs may overcome immunotherapy resistance in tumors

Researchers at the UCLA Jonsson Comprehensive Cancer Center have found that a drug that activates the body's natural defenses by behaving like a virus may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy.

15 Oct 2020

Immunotherapy using CAR NKT cells shows promise for treating solid tumors

Natural killer T (NKT) cells, a type of immune cells known for their potent anti-cancer properties in murine tumor models, have been developed into a novel form of immunotherapy to treat patients with cancer.

14 Oct 2020